Baseline insulin levels at time of prostate cancer diagnosis have also been shown to be the most significant predictor of lethal prostate cancer, strongly suggesting that insulin is a major factor in prostate cancer progression associated with metabolic dysfunction [35]. This evidence concerns the gene INS and prostate carcinoma.